The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Updated pathophysiology of rheumatoid arthritis

최근 조명된 류마티스 관절염의 병태 생리

Song, Yeong-Wook
송영욱

  • Published : 20090100
⟨ Previous Next ⟩

Abstract

Rheumatoid arthritis is a chronic inflammatory disease that primarily affects joint synovium. Although its etiology has yet to be identified, the underlying mechanism of joint inflammation is understood as autoimmune process. The inflamed synovium is thickened due to synovial hyperplasia and infiltrating mononuclear cells such as T and B lymphocytes, macrophages, and plasma cells. Key inflammatory cytokines TNF-${\alpha}$ and IL-1, as shown by the significant therapeutic effect of their blockade, are mainly secreted by macrophages whereas IL-17 is secreted by a newly recognized subset of T cells (Th17 cells) and induces TNF-${\alpha}$ and IL-1 production by adjacent macrophages, synoviocytes, and chondrocytes. IL-17 has also been shown to induce RANKL from osteoblasts, thereby indicating that this cytokine plays as an upstream molecule that regulates inflammation and osteoclastogenesis. More importantly, IL-17 has been shown to convert acute inflammation into chronic inflammation and when combined with already important cytokines, more marked inflammation occurs. The role of B cells as antigen presenting cells are now being recognized based on the therapeutic effect of rituximab, a B cell inhibitor, in rheumatoid arthritis. Great attention has been turned to anti-citrullinated peptide antibodies because they form immune complex and contribute to inflammation by activating complement system. Recently, clinical trials showed therapeutic efficacy of tocilizumab, monoclonal antibody against IL-6 receptor, suggesting relevant involvement of IL-6 in disease process of rheumatoid arthritis. Thus, various cellular and molecular players seem to interact within rheumatoid synovium to perpetuate inflammation. Further studies are needed to explore the exact mechanisms of development and maintenance of inflammation in rheumatoid arthritis.

Keywords

References

  1. Lee DM, Weinblatt ME. Rheumatoid arthritis Lancet 358:903-901, 2001 https://doi.org/10.1016/S0140-6736(01)06075-5
  2. Gay S, Koopman WJ. Immunopathology of rheumatoid arthritis. Curr Opin Rheumatol 1:8-14, 1989 https://doi.org/10.1097/00002281-198901010-00004
  3. FitzGerald O, Soden M, Yanni G, Robinson R, Bresnihan B. Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis 50:792-796, 1991 https://doi.org/10.1136/ard.50.11.792
  4. Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol 24:1253-1259, 1997
  5. Girard JP, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 16:449-457, 1995 https://doi.org/10.1016/0167-5699(95)80023-9
  6. Shiozawa S, Shiozawa K, Fujita T. Morphologic observations in the early phase of the cartilage-pannus junction. Light and electron microscopic studies of active cellular pannus. Arthritis Rheum 26:472-478, 1983 https://doi.org/10.1002/art.1780260404
  7. Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol 13:899-902, 1986
  8. Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 32:903-907, 1993 https://doi.org/10.1093/rheumatology/32.10.903
  9. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43:30-37, 2000 https://doi.org/10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B
  10. Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, Bell JI. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A 86:10049-10053, 1989 https://doi.org/10.1073/pnas.86.24.10049
  11. Ronningen KS, Spurkland A, Egeland T, Iwe T, Munthe E, Vartdal F, Thorsby E. Rheumatoid arthritis may be primarily associated with HLA-DR4 molecules sharing a particular sequence at residues 67-74. Tissue Antigens 36:235-240, 1990 https://doi.org/10.1111/j.1399-0039.1990.tb01834.x
  12. Hong G, Park MH, Takeuchi F, Oh MD, Song YW, Nabeta H, Nakano K, Ito K and Park KS. Association of specific amino acid sequence of HLA-DR with rheumatoid arthritis in Koreans and its diagnostic value. J Rheumatol 23:1699-1703,1996
  13. Holborow EJ. The relationship of autoimmunity to rheumatoid arthritis. Proc R Soc Med 57:59-62, 1964
  14. Nykanen P, Bergroth V, Raunio P, Nordstr$\ddot{o}$m D, Konttinen YT. Phenotypic characterization of 3H-thymidine incorporating cells in rheumatoid arthritis synovial membrane. Rheumatol Int 6:269-271, 1986 https://doi.org/10.1007/BF00541318
  15. Kohem CL, Brezinschek RI, Wisbey H, Tortorella C, Lipsky PE, Oppenheimer-Marks N. Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 39:844-854, 1996 https://doi.org/10.1002/art.1780390518
  16. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440, 1996 https://doi.org/10.1146/annurev.immunol.14.1.397
  17. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 370:1861-1874, 2007 https://doi.org/10.1016/S0140-6736(07)60784-3
  18. Firestein G.S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: Passive responders or transformed aggressors? Arthritis Rheum 39:1781-1790, 1996 https://doi.org/10.1002/art.1780391103
  19. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44:1003-1012, 2001 https://doi.org/10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#
  20. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997 https://doi.org/10.1016/S0092-8674(00)80209-3
  21. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 162:1246-1251, 1999
  22. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42:963-970, 1999 https://doi.org/10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E
  23. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine, 41:84-91. 2008 https://doi.org/10.1016/j.cyto.2007.09.014
  24. Lubberts E, Schwarzenberger P, Huang W, Schurr JR, Peschon JJ, van den Berg WB, Kolls JK. Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J Immunol 175:3360-3368, 2005 https://doi.org/10.4049/jimmunol.175.5.3360
  25. Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 44:1293-1303, 2001 https://doi.org/10.1002/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T
  26. Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, Tomooka BH, Gregersen PK, Robinson WH. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 10:R94, 2008 https://doi.org/10.1186/ar2478
  27. van Venrooij WJ, Pruijn GJ. An important step towards completing the rheumatoid arthritis cycle. Arthritis Res Ther 10:117-119, 2008 https://doi.org/10.1186/ar2504
  28. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM, Hueber W, Robinson WH, Cairns E. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 205:967-979, 2008 https://doi.org/10.1084/jem.20072051
  29. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 128:127-137, 1998 https://doi.org/10.7326/0003-4819-128-2-199801150-00009
  30. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11:88-95, 1996 https://doi.org/10.1002/jbmr.5650110113
  31. Tanabe M, Ochi T, Tomita T, Suzuki R, Sakata T, Shimaoka Y, Nakagawa S, Ono K. Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol 21:830-835, 1994
  32. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized antiinterleukin- 6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50:1761-1769, 2004 https://doi.org/10.1002/art.20303
  33. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817-2829, 2006 https://doi.org/10.1002/art.22033
  34. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T. Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, An IL-6 Inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 66:1162-1167, 2007 https://doi.org/10.1136/ard.2006.068064
  35. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiographic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 50:36-42, 2004 https://doi.org/10.1002/art.11481
  36. Kirwan JR. The synovium in rheumatoid arthritis: evidence for (at least) two pathologies. Arthritis Rheum 50:1-4, 2004 https://doi.org/10.1002/art.11496
  37. Boers M. Pathophysiology of rheumatoid arthritis: split or lump? Arthritis Rheum 58:2925-2927, 2008 https://doi.org/10.1002/art.23944
  38. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 58:2958-2967, 2008 https://doi.org/10.1002/art.23945